Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Tenaya Therapeutics (TNYA)
NASDAQ:TNYA
Holding TNYA?
Track your performance easily
TNYA Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$1.61 - $7.01
Previous Close$3.57
Volume4.62M
Average Volume (3M)2.57M
Market Cap
$282.82M
Enterprise Value$217.89M
Total Cash (Recent Filing)$79.47M
Total Debt (Recent Filing)$14.54M
Price to Earnings (P/E)―
Beta3.24
Next Earnings
Mar 25, 2025EPS Estimate
-$0.31Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.48
Shares Outstanding79,220,516
10 Day Avg. Volume5,250,962
30 Day Avg. Volume2,573,163
Standard Deviation0.30
R-Squared0.15
Alpha-0.03
Financial Highlights & Ratios
Price to Book (P/B)1.56
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-2.30
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit10.00T>
Enterprise Value/Ebitda-2.03
Forecast
1Y Price Target
$22.00Price Target Upside516.25% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering8
Tenaya Therapeutics News
PremiumCompany Announcements
Tenaya Therapeutics Reports Q3 2024 Progress and Financial Results
PremiumStock Analysis & Ideas
Morgan Stanley Predicts Up to 670% Jump for These 2 ‘Strong Buy’ Stocks
PremiumCompany Announcements
Tenaya Therapeutics Announces Board Restructuring and New Equity PlanBulls Say, Bears Say
Bulls Say
Clinical TrialsThe commencement of the RIDGE-1 Phase 1 study marks an important milestone for Tenaya, as the first patient has been dosed with TN-401, aiming to treat arrhythmogenic right ventricular cardiomyopathy (ARVC).
Financial PerformanceAnalyst maintains a BUY rating and has increased the price target from $16 to $18, reflecting optimism about the company's future prospects.
Research And DevelopmentTN-401's potential efficacy in ARVC is supported by robust preclinical data and IND enabling studies, indicating a promising future for the therapy.
Bears Say
Financial PerformanceTNYA reported a net loss of $25.6 million for the third quarter of 2024.
Financial StabilityThe company has approximately one year of cash runway, excluding a $45 million credit facility.
Research And DevelopmentTN-301 remains shelved as the company seeks a suitable partner for its development.
---
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
TNYA FAQ
What was Tenaya Therapeutics’s price range in the past 12 months?
Tenaya Therapeutics lowest stock price was $1.61 and its highest was $7.01 in the past 12 months.
What is Tenaya Therapeutics’s market cap?
Currently, no data Available
When is Tenaya Therapeutics’s upcoming earnings report date?
Tenaya Therapeutics’s upcoming earnings report date is Mar 25, 2025 which is in 104 days.
How were Tenaya Therapeutics’s earnings last quarter?
Tenaya Therapeutics released its earnings results on Nov 06, 2024. The company reported -$0.3 earnings per share for the quarter, beating the consensus estimate of -$0.368 by $0.068.
Is Tenaya Therapeutics overvalued?
According to Wall Street analysts Tenaya Therapeutics’s price is currently Undervalued.
Does Tenaya Therapeutics pay dividends?
Tenaya Therapeutics does not currently pay dividends.
What is Tenaya Therapeutics’s EPS estimate?
Tenaya Therapeutics’s EPS estimate is -$0.31.
How many shares outstanding does Tenaya Therapeutics have?
Tenaya Therapeutics has 79,220,510 shares outstanding.
What happened to Tenaya Therapeutics’s price movement after its last earnings report?
Tenaya Therapeutics reported an EPS of -$0.3 in its last earnings report, beating expectations of -$0.368. Following the earnings report the stock price went up 12.108%.
Which hedge fund is a major shareholder of Tenaya Therapeutics?
Among the largest hedge funds holding Tenaya Therapeutics’s share is RA Capital Management. It holds Tenaya Therapeutics’s shares valued at 13M.
---
Tenaya Therapeutics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$22.00 (516.25% Upside)
$22.00 (516.25% Upside)
Hedge Fund Trend
Decreased
By 743.7K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $4.8K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▲ 2.1%
Last 30 Days ▲ 104.2%
Last 30 Days ▲ 104.2%
Technicals
SMA
Negative
20 days / 200 days
Momentum
91.93%
12-Months-Change
Fundamentals
Return on Equity
-84.49%
Trailing 12-Months
Asset Growth
-27.31%
Trailing 12-Months
Company Description
Tenaya Therapeutics
Tenaya Therapeutics Inc is a preclinical stage biotechnology company focused on discovering, developing, and delivering curative therapies that address the underlying drivers of heart disease. It is advancing product candidates from three product platforms: gene therapy, cellular regeneration, and precision medicine.
---
TNYA Stock 12 Month Forecast
Average Price Target
$22.00
▲(516.25% Upside)
Technical Analysis
Allogene Therapeutics
―
Fate Therapeutics
―
Intellia Therapeutics
―
Crispr Therapeutics AG
―
Best Analysts Covering TNYA
1 Year
1 Year Success Rate
5/9 ratings generated profit
1 Year Average Return
+13.52%
reiterated a buy rating 17 days ago
Copying Joseph Pantginis's trades and holding each position for 1 Year would result in 55.56% of your transactions generating a profit, with an average return of +13.52% per trade.
---